Sai Parenteral’s Limited IPO Day 3: GMP ₹0, Subscription 0.4x
As the Initial Public Offering (IPO) of Sai Parenteral’s Limited enters its final day, investors are closely watching the subscription numbers. The mainboard IPO on the NSE, which opened for subscription on March 24, 2026, and closes on March 27, 2026, has seen mixed interest across different investor categories on Day 3.
| Date | GMP | Est. Listing |
|---|---|---|
| 02 Apr | ₹0 | ₹392 |
| 01 Apr | ₹0 | ₹392 |
| 31 Mar | ₹0 | ₹392 |
| 30 Mar | ₹0 | ₹392 |
| 28 Mar | ₹0 | ₹392 |
Subscription Status
The overall subscription for Sai Parenteral’s Limited IPO stands at 0.41 times on Day 3. Breaking down the category-wise subscription reveals varying investor sentiment:
- Retail: This segment is currently subscribed at 0.05 times, indicating a lukewarm response from individual investors.
- Non-Institutional Investors (NII): The NII category is performing well, with a subscription of 1.01 times. This suggests strong interest from high-net-worth individuals and corporate bodies.
- Qualified Institutional Buyers (QIB): The QIB segment is subscribed at 0.6 times. This indicates a moderate level of interest from institutional investors.
The NII category’s oversubscription is a positive sign, but the low retail subscription might be a point of concern for some. The total subscription of 0.41x means that for every share offered, on average, 0.41 applications have been received.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 0.12x | |
| NII / HNI | 2.36x | |
| QIB | 1.71x | |
| Total | 1.05x |
| Date | Retail | NII | QIB | Total |
|---|---|---|---|---|
| 25 Mar | 0.05x | 1.01x | 0.60x | 0.41x |
| 24 Mar | 0.03x | 0.15x | 0.00x | 0.04x |
GMP Update
The Grey Market Premium (GMP) for Sai Parenteral’s Limited IPO has remained unchanged. The current GMP is ₹0, which is the same as yesterday’s figure. A GMP of ₹0 suggests that the market is currently not pricing in any premium over the issue price of ₹392. This implies that the expected listing price is likely to be around the issue price of ₹392, with no significant gains anticipated in the grey market immediately post-listing.
Should You Apply?
The decision to apply for the Sai Parenteral’s Limited IPO hinges on a balanced assessment of the subscription data and the GMP. While the NII category shows robust interest, the subdued retail subscription and the zero GMP warrant careful consideration. Investors should also consult their financial advisors and review the SEBI-registered investment advisors’ recommendations before making an investment decision.
The IPO is offering 38 shares per lot, and the issue price is ₹392 per share. The IPO period is from 2026-03-24 to 2026-03-27.
View Full Sai Parenteral’s Limited IPO Details